Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron

Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron

SHERBROOKE, QC, Jan. 10, 2022 /CNW Telbec/ Immune Biosolutions Inc., a clinical-stage company, is pleased to announce that its leading biological drug…

Promising treatment against COVID-19 and its variants: Quebec biotech, Immune Biosolutions begins Phase I clinical trial stages for its inhaled immunotherapy treatment

Immune Biosolutions is pleased to announce the start of Phase I clinical trial for its immunotherapy (IBIO123) treatment, whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. The treatment has the ability of being administered by inhalation and acts in a highly targeted manner through the lungs to fight the infection at its source.